Q-omics provides the consensus-scored TSPAN3 profile across patient tissues and cancer cell-line models. TSPAN3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TSPAN3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TSPAN3 protein abundance shows 27,530 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, KICH, and LUAD as cancer lineages where TSPAN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN3 survival associations across molecular data types. TSPAN3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN3 RNA expression–survival associations across cancer types. High TSPAN3 expression shows unfavorable associations in UVM and KIRP, but favorable associations in KIRC, MESO, OV and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TSPAN3 RNA expression.
This table summarizes TSPAN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN3 shows lower tumor expression in KICH, LUSC, BRCA, READ and COAD and higher tumor expression in LIHC. The KICH box plot shows higher TSPAN3 RNA expression in normal versus tumor tissue (log2 FC = −1.009, t-test p < 0.001).
This table shows molecular features associated with TSPAN3 in patient tissues and cancer cell lines. In patient samples, TSPAN3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
